Merck and Eli Lilly Prepare for Third-Quarter Earnings Reports
Pharmaceutical leaders Merck (MRK) and Eli Lilly (LLY) are set to release their third-quarter financial results on October 29. Market analysts anticipate a year-on-year decline in earnings for both companies, signaling a challenging period for these industry giants. Specifically, Merck is projected to see its per-share earnings decrease by 19% to $2.09. Investors are closely watching these reports to gauge the impact of current market conditions and product performance on the broader pharmaceutical sector.
Coverage
- NL Industries reports Q3 results
- LSI Industries reports Q1 results
- Eli Lilly Raises Price Target Amid Strong Third Quarter Earnings and Obesity Drug Growth
- Eli Lilly Set to Report Third-Quarter Earnings Driven by Obesity and Diabetes Drugs
- Alphabet Prepares for Third-Quarter Earnings Amid AI Infrastructure Cost Concerns
- Merck and Eli Lilly Prepare for Third-Quarter Earnings Reports